Climb Bio, Inc. (NASDAQ:CLYM - Free Report) - Stock analysts at Leerink Partnrs decreased their Q2 2025 earnings estimates for Climb Bio in a research report issued to clients and investors on Wednesday, May 14th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings of ($0.18) per share for the quarter, down from their previous estimate of ($0.15). The consensus estimate for Climb Bio's current full-year earnings is ($1.57) per share. Leerink Partnrs also issued estimates for Climb Bio's Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.89) EPS, FY2026 earnings at ($0.98) EPS, FY2027 earnings at ($1.18) EPS, FY2028 earnings at ($1.84) EPS and FY2029 earnings at ($2.85) EPS.
Climb Bio (NASDAQ:CLYM - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.16).
Separately, BTIG Research assumed coverage on Climb Bio in a research report on Thursday. They issued a "buy" rating for the company.
Get Our Latest Stock Analysis on CLYM
Climb Bio Stock Performance
Shares of CLYM stock traded down $0.02 during mid-day trading on Monday, hitting $1.18. The company's stock had a trading volume of 178,602 shares, compared to its average volume of 281,402. Climb Bio has a 52-week low of $1.05 and a 52-week high of $9.58. The company has a 50-day moving average of $1.25. The firm has a market capitalization of $79.74 million, a PE ratio of -0.55 and a beta of -0.12.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the stock. RA Capital Management L.P. purchased a new stake in Climb Bio during the 1st quarter valued at $38,332,000. Affinity Asset Advisors LLC purchased a new stake in Climb Bio during the first quarter valued at $1,830,000. Peapod Lane Capital LLC purchased a new stake in Climb Bio during the first quarter valued at $676,000. Allostery Investments LP purchased a new stake in Climb Bio during the first quarter valued at $299,000. Finally, Persistent Asset Partners Ltd purchased a new stake in Climb Bio during the first quarter valued at $178,000. 69.76% of the stock is owned by hedge funds and other institutional investors.
About Climb Bio
(
Get Free Report)
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.
See Also
Before you consider Climb Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Climb Bio wasn't on the list.
While Climb Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
